Loading company
LLYELI Lilly And Company$1.35TA+Just reported
From Amgen's results release of November 3, 2026; its quarterly report has since been filed.
Actual
$10.37B
+8.5% y/y
+3.1% q/q
Guided
—
No guide given
Actual
$7.08
+19% y/y
+62% q/q
Guided
—
No guide given
Actual
$3.71B
+47% y/y
+5.6% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Shares of revenue are estimates for year ended 2025-12-31, high confidence, not figures from a filing.
Repatha
An injectable medicine that lowers LDL cholesterol and is used to reduce the chance of major heart and blood-vessel events in certain adults.
Prolia
A medicine for osteoporosis that helps reduce fracture risk in certain people, including postmenopausal women and men at high risk of fracture.
Otezla
An oral medicine used for plaque psoriasis, psoriatic arthritis and certain mouth ulcers.
ENBREL
A medicine used for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
TEZSPIRE
An antibody medicine used as an add-on treatment for severe uncontrolled asthma and, in approved markets, chronic sinus inflammation with nasal polyps.
IMDELLTRA
A cancer medicine for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.
Amgen researches, develops and manufactures medicines, including biologic medicines made using living cells and small-molecule drugs. It sells treatments for conditions including heart disease, cancer, osteoporosis, asthma and autoimmune diseases. It also sells biosimilar medicines, which are highly similar versions of existing biologic medicines.
Built from Amgen Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Amgen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$468.13+0.6%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Amgen discovers, makes and sells prescription medicines for serious diseases, along with biosimilar medicines.
Company outlook: revenue of $38.9B to $39.7B for Fiscal year 2026 — up 6.9% on a year earlier
Grade A+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Amgen Inc.’s grade history. The other 39 go back to October 2016.
